Hugel's 'Letibo' Expands to 30 Countries in Europe

Obtained Product Approval in Lithuania, Bulgaria, and Others

Hugel recently announced on the 16th that it has obtained product approval for its botulinum toxin (BTX) 'Letibo' (domestic name: Botulex) in Lithuania, Bulgaria, Iceland, and Croatia.

Hugel's Botulinum Toxin 'Letibo'
[Photo by Hugel]

With this approval, Letibo has successfully entered 30 countries, including the Big 5 in Europe?Germany, the United Kingdom, France, Italy, and Spain?rapidly expanding its market presence. After receiving a positive product approval opinion from the Heads of Medicines Agencies (HMA) in January 2022, Letibo made its first shipment to France and Austria in March, becoming the first domestically produced BTX to successfully launch in the European local market. Europe is considered one of the world's three major BTX markets alongside the United States and China. In particular, interest and awareness in medical aesthetic procedures are rapidly growing, diversifying the age groups undergoing treatments and increasing the influx of male consumers.

A Hugel representative stated, “Based on the excellent quality and efficacy as the number one BTX product in the domestic market for seven consecutive years, we will enhance our influence in the European market,” adding, “We will continue to strengthen differentiated sales and marketing strategies tailored to local market characteristics, as well as our network with medical professionals.”